{
  "docId": "019de077-0326-7579-845c-ff13347b3147",
  "docSlug": "a6759fd47798a8f3f6e744ad8917865e",
  "documentTitle": "Exscientia | Investor Presentation Deck | 93 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 89,
  "pageCount": 93,
  "prevPage": 88,
  "nextPage": 90,
  "slideType": "product_demo",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses dose-response curves to show IC50 and selectivity.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0326-7579-845c-ff13347b3147/89",
  "deckHref": "/decks/019de077-0326-7579-845c-ff13347b3147",
  "deckJsonHref": "/decks/019de077-0326-7579-845c-ff13347b3147.json",
  "deckAnchorHref": "/decks/019de077-0326-7579-845c-ff13347b3147#slide-89",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.08,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Dose-response curve for CLL cells",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c12a1a53-cd7d-4771-b645-0ec15ef9aa6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.4,
        "x": 0.52,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Dose-response curve for T-cells",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7a46a40-f72c-4bfd-a82e-3ec342960830",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.12,
        "y": 0.72
      },
      "kind": "list",
      "text": "CLL samples from both treatment naïve patients and patients exposed to previous lines of therapy; ‘565 selectively inhibited the proliferation of primary human CLL cells; Limited impact of ‘565 observed on T-cell viability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ce89a3f-35c2-4f0e-950b-1bb732948196",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Efficacy in primary human tissues without impacting T-cell viability",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43bb61fc-ff9e-4765-86c1-11d09e129b85",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "‘565 inhibits primary human CLL cell proliferation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa58f227-ec0a-4656-9851-6fba3011b5a0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}